Total oxidant–antioxidant and paraoxonase-1 levels in premenstrual dysphoric disorder: a follow-up study

Halil Ozcana, Elif Oralb, Mustafa Gulecb, Hasan Turkezc, Tezay Cakin Gulecd, Mehmet Fatih Ustundaga, Unsal Aydinoglue and Atakan Yucela

dDepartment of Psychiatry, School of Medicine, Ataturk University, Erzurum, Turkey; bDepartment of Psychiatry, School of Medicine, Katip Celebi University, Izmir, Turkey; cDepartment of Molecular Biology and Genetics, School of Science, Erzurum Technical University, Erzurum, Turkey; dDepartment of Neurology, Turkan Ozilhan Bornova State Hospital, Izmir, Turkey; eDepartment of Psychiatry, Kastamonu Dr. Munif İslamoglu State Hospital, Kastamonu, Turkey

ABSTRACT

Objective: Premenstrual dysphoric disorder (PMDD) is a severe form of premenstrual syndrome (PMS) that was categorized as a mood disorder in the most recent version of the Diagnostic and Statistical Manual for Mental Disorders. In addition to a history of PMS, a PMDD diagnosis requires prospective symptom assessment for 2 consecutive menstrual periods. Although the effects of some oxidants–antioxidants were previously studied in PMS, their possible effects in PMDD remain unknown. Paraoxonase-1 (PON-1) is a new high-density lipoprotein-associated enzyme with many antioxidative effects. We hypothesized that assessing serum total oxidant–antioxidant and PON-1 levels could clarify the role of oxidant–antioxidant system in PMDD.

Methods: All participants (n = 50) were assessed by an experienced psychiatrist for PMDD by using the Diagnostic and Statistical Manual for Mental Disorders-IV (DSM-IV), Premenstrual Assessment Form and Daily Record of Severity of Problems (DRSP)-Short Form or possible psychiatric disorders including depression, anxiety, and sleep disorders. Serum estrogen, progesterone, total oxidant–antioxidant, and paraoxonase-1 (PON-1) levels were measured in the serum of 20 participants with PMDD and 30 asymptomatic controls during the follicular and luteal phases of two consecutive menstrual cycles. Sleep quality, depression, and anxiety symptoms were assessed with the Pittsburg Sleep Quality Index (PSQI), Hamilton Depression Rating Scale (HDRS), and Hamilton Anxiety Rating Scale (HARS), respectively.

Results: There were no significant intergroup differences in estrogen, progesterone, oxidant–antioxidant, or PON-1 levels or PSQI scores. However, the mean HDRS and HARS scores were statistically significantly higher for patients with PMDD than for controls. Levels of estrogen, progesterone, and total oxidant–antioxidant were not correlated with HDRS, HARS, or PSQI scores.

Conclusions: Considering the lack of differences in hormonal and biochemical levels between the two groups, it may be more efficient and discriminative to longitudinally assess biochemical and cellular stress-related parameters in subjects with PMDD.

Introduction

It is estimated that at least 75% of women experience minor premenstrual symptoms [1], and 20–32% and 3–8% would fulfill the diagnostic criteria for premenstrual syndrome (PMS) and premenstrual dysphoric disorder (PMDD), respectively [2,3]. PMDD, which was first defined as a severe form of PMS in the fourth text revision of the DSM-IV TR, was listed as a depressive disorder in the DSM-5, and a diagnosis requires the prospective assessment of two consecutive menstrual periods [4–6].

PMDD is a cyclic pattern of symptoms that begins during the late luteal phase of the menstrual cycle and subsides shortly after the onset of menstruation; it is diagnosed by the existence of at least one affective symptom (depressed mood, anxiety, affective lability, marked anger, or irritability) and five or more total symptoms including affective symptoms [4,5]. Numerous biological factors have been proposed to influence PMDD pathogenesis, including progesterone deficiency, serotonergic dysfunction, and disturbed endorphin modulation by gonadal steroids and their products [7–11]. Environmental and nutritional factors including lack of exercise and poor dietary habits have also been blamed for PMDD [12]. Interestingly, a growing body of evidence suggests that subjects with PMDD have normal ovulatory conditions and do not show evidence of hormonal imbalances [13–15]. Oxidative stress is a situation that reflects an imbalance between oxidant production and antioxidant defenses [16,17]. Measuring the total antioxidant capacity (TAC) requires the simultaneous quantification of...
of several antioxidant markers and is one indicator of oxidative status [5]. Oxidative stress may lead to premature cell death and is associated with many ischemic and inflammatory diseases, degenerative disorders, and psychiatric disorders such as depression, bipolar disorder, schizophrenia, obsessive compulsive disorder, sleep disorders, and anxiety disorders [18–23]. In addition, almost all steps of inflammation and cellular immune activation have been linked to depression pathogenesis [24–28]. Besides depressive symptoms, PMDD may involve increased inflammatory processes because it involves the influx of a large amount of inflammatory cells [29]. The inflammatory processes that may trigger tissue desquamation at mensturation remain to be clarified, but some studies have shown alterations in inflammation markers in relation to menstrual phases [30] and premenstrual symptom severity [31]. A recent study described increased lipid hydroperoxide, which is commonly used to assess oxidative levels, and decreased TAC in subjects with PMS in their luteal phases [5]. Another group reported that subjects with PMS had total oxidant status (TOS) levels non-significantly higher that and TAC levels similar with those of controls [32]. In another study, elevated levels of nitric oxide (NO), a well-known antioxidant, were reported in PMS patients at the beginning of the menstrual cycle. Therefore, it was suggested that the increasing NO levels at the follicular phase of the menstrual cycle were involved in the alleviation of PMS symptoms that after mensturation onset [33]. PON-1 is a high-density lipoprotein-associated enzyme with many antioxidative effects. Decreased PON-1 plasma activity was found to be a trait marker for major depression [34]. However, PON-1 levels have not yet been examined in PMDD.

In this study, we aimed to determine whether there are measurable differences in total oxidant statuses and antioxidant capacity levels in subjects with PMDD. We investigated sleep quality; symptoms of depression and anxiety; and the levels of serum ovarian hormones (estrogen and progesterone), total oxidant–antioxidant, and PON-1 levels in four consecutive blood samples during the follicular and luteal phases of two consecutive menstrual cycles.

Material and methods

Study design and setting

This was a prospective cohort study conducted at our university hospital after the study protocol was approved by the local ethics committee and all participants provided written informed consents. Between September and November 2012, 550 participants were randomly selected from the population of female medical students at the university. After a clinical evaluation procedure, 71 participants were selected for follow-up during two consecutive menstrual cycles.

At the end of their second menstrual cycle, their records were analyzed, and 20 participants were diagnosed with PMDD. Although 37 participants had no premenstrual symptoms, 2 of them did not attend the study sessions, and 5 of the asymptomatic participants were not interested in completing the following assessments and did not provide a reason. Ultimately, 30 participants who had no premenstrual symptoms were enrolled as the control group. The exclusion and inclusion criteria, assessment steps, and participant recruitment are summarized in Figure 1.

Procedure and participants

During the follow-up period, an experienced psychiatrist assessed all participants (n = 50) for PMDD based on the Diagnostic and Statistical Manual for Mental Disorders-IV (DSM-IV) and DRSP-Short Form or possible psychiatric disorders including depression, anxiety, and sleep disorders. The participants underwent a medical examination and blood sampling. Serum TOS, TAC, estrogen, progesterone, and PON-1 levels were assessed during the luteal (days 21–25) and follicular (days 6–8) phases of 2 consecutive menstrual cycles in all 50 subjects. Ovulation was determined by evaluating plasma progesterone levels on day 21 (the subject was considered to be ovulating when plasma progesterone levels were ≥10.0 ng/mL). Sleep quality and depressive and anxiety-related symptoms were assessed at the first and second luteal phases using the instruments listed below.

Instruments

Sociodemographic data form

Each participant completed a data form that asked about dysmenorrhea, nutritional habits, smoking habits, exercise levels, and caffeine consumption.

Daily Record of Severity of Problems

This tool was developed by Endicott et al. [35] to aid the diagnosis and evaluation of DSM-IV PMS. To enhance the assessment of specific DSM-IV PMDD criteria, the 11 physical and psychological symptoms from criterion A were described using 11 separate items in the short form. An additional three items described specific types of functional impairment caused by the symptoms. The participants were asked to fill out the DRSP every day during two consecutive menstrual cycles. A six-point severity scale was used to score each item “to indicate the degree to which the problems were experienced.” Participants who scored at least 4 in depressive symptoms and irritability items, ≥4 in 5 of the 11 items, and ≥4 in functionality items (items 12–14) for at least 2 days during their luteal phase (days 21–25) for 2 consecutive cycles were diagnosed as having PMDD.
The Premenstrual Assessment Form

This form was developed to categorize reported premenstrual changes. The development of the Premenstrual Assessment Form (PAF) and its categorical and dimensional scoring systems are described in detail elsewhere [12,36]. The PAF comprises 95 items, each of which are rated using a 6-point severity scale that focuses on the degree of change from the typical premenstrual state to that during the full menses flow.

Pittsburg Sleep Quality Index

The Pittsburg Sleep Quality Index (PSQI) includes 19 items that measure different aspects of sleep quality and sleep disturbances during a 1-month period. A cut-off score of 5 was found to correctly identify 88.5% of patients with sleep disturbances. The sum of scores yields a global score that ranges from 0 to 21, with higher scores indicating poorer sleep quality [37,38].

The Hamilton Depression Rating Scale

The Hamilton Depression Rating Scale (HDRS) comprises 17 items selected to measure the severity and variability of depression symptoms. Higher scores indicate more severe depression [39,40].

The Hamilton Anxiety Rating Scale

The HARS includes 14 items designed to measure the severity and variability of anxiety symptoms. Higher scores indicate more severe anxiety [41,42].

Protocol

Four consecutive fasting blood samples were obtained from each participant at two different menstrual periods between 8:00 and 9:00 am by venipuncture and were collected in anticoagulant-free vacuum tubes. The samples were allowed to clot and then centrifuged at 3500 g for 5 min. Serum aliquots were stored at −80°C and thawed immediately prior to the measurement of biochemical parameters.

Estrogen and progesterone assessment

Estrogen and progesterone serum concentrations were determined using commercially available radioimmunoassay kits (RadimSpA®, Pomezia, Italy).

Automated TAC and TOS assays were performed using plasma samples from healthy volunteers and patients using commercially available kits (Rel Assay Diagnostics®, Gaziantep, Turkey).

A fully automated assay for PON-1 activity in plasma samples used commercially available kits (Rel Assay Diagnostics®) containing two different sequential reagents [43].

Data analysis

Descriptive statistics were used to assess sociodemographic data and analyze participant scale scores. The Kolmogorov–Smirnov test was used to test the hypothesis that the distribution was normal. Independent
sample t or Mann–Whitney U tests were performed to compare the serum total oxidant–antioxidant, estrogen, and progesterone levels between the control and PMDD groups. Spearman correlation analyses were used to examine relationships between biochemical, hormonal, and other parameters. Analyses for total oxidant–antioxidant, progesterone, and estrogen levels were performed for both menstrual cycles in both the luteal and follicular phases. Two-way repeated-measures analyses of variance (ANOVAs) were used to assess the luteal and follicular differences between dependent variables (biochemical parameters) in the factors (groups and menstrual phases).

**Results**

The mean ages and body mass indexes of the PMDD and control groups were 21.8 ± 1.4 and 21.6 ± 1.8 years and 21.7 ± 2.1 and 21.2 ± 2.0 kg/m², respectively. There were no statistically significant differences between groups in terms of age, BMI, mean menstruation duration, or age at menarche. There were no statistically significant differences in the mean estrogen and progesterone levels in the PMDD and control groups (83.4 ± 28.4 pg/mL vs. 100.6 ± 56.6 pg/mL and 5.0 ± 3.9 vs. 5.8 ± 5.4 pg/mL, respectively). Their nutritional habits, exercise levels, and caffeine consumptions were also similar. Some of the participants diagnosed with PMDD were also diagnosed with minor-moderate depression (4/20), anxiety disorder (2/20), and primary insomnia (1/20). None of the controls were diagnosed with any of these conditions.

Total antioxidant and PON-1 levels did not differ between the PMDD and control groups in the luteal or follicular phases of the two menstrual cycles (Table 1). Total antioxidant levels in both the phases were similar between the PMDD and control group, but total oxidant levels were statistically significantly lower in the PMDD group compared to controls in the second follicular phase (Table 2).

The changes (Δ) in total antioxidant, estrogen, and progesterone levels were similar between the PMDD and control group in both menstrual cycle phases (Table 2). However, the ΔPON-1 in the PMDD group was statistically significantly higher in the luteal phase compared to the control group. We expected an increase in TOS in the PMDD group, but TOS was statistically significantly lower in the PMDD group in the second follicular phase compared to controls (Table 2).

We also evaluated the total antioxidant/total oxidant ratio. No statistically significant difference was found in the luteal, follicular, mean, or Δtotal antioxidant/total oxidant ratio between the PMDD patients and controls in either cycle.

Two-way ANOVAs revealed no statistically significant differences between the groups in terms of TAC, TOS, or PON-1 levels (Figures 2–4). The respective f- and p-values were 0.601 and .616 for TAC, 1.164 and .327 for TOS, and 0.238 and .849 for PON-1.

The mean HDRS scores were higher for patients with PMDD than for controls in (8.2 ± 4.2 vs. 5.3 ± 5.2, p = .047) and HARS scores were higher for patients with PMDD than for controls (15.0 ± 6.4 vs. 11.0 ± 8.7, p = .046), respectively.

As PMDD is known for symptoms that occur during the luteal phase, we examined the correlation between luteal phase blood markers and clinical symptoms (Only statistically significant results on correlation analysis were given for PMDD group). The TAC was statistically significantly, negatively and strongly correlated with PON-1 levels (r = −0.729, p < .001) in the luteal phase. TAC and PON-1 in the PMDD group was statistically significantly higher in the luteal phase compared to controls (r = −0.474, p = .06). The luteal HARS score was negatively and far to statistically significantly correlated with mean PON-1 in the luteal phase (r = −0.474, p = .06). The HDRS and PSQI scores did not show any statistically significant correlation with oxidant, antioxidant, PON-1, estrogen, or progesterone levels. The mean luteal progesterone level was negatively, moderately and statistically significantly correlated with mean luteal antioxidant level (r = −0.628, p = .005). The total PAF score that evaluates the premenstrual symptom severity was positively, mildly, and statistically significantly correlated with total oxidant levels in second follicular phase (r = 0.559, p = .03) and was positively, mildly, and statistically significantly correlated with Δestrogen levels in both luteal phases (for both r = 0.505, p = .33).

**Discussion**

In this study, although total antioxidant and PON-1 levels did not differ between the PMDD and control groups in the luteal or follicular phases of the two menstrual cycles, total oxidant levels were statistically significantly lower in the PMDD group compared to controls in the second follicular phase. Additionally, ΔPON-1 in the PMDD group was statistically significantly higher in the luteal phase compared to the control group. Also, we found opposite patterns for serum TAC, TOS, and PON-1 in PMDD and controls.

### Table 1. TAC, TOS, and PON-1 levels in patients with PMDD and controls (Student’s t-test).

| Biochemical assessment       | PMDD Mean ± SD | Control Mean ± SD | p  |
|------------------------------|----------------|-------------------|----|
| TOS (Total Oxidant Status, Eq/L) | 36.9 ± 12     | 35.4 ± 7.2        | .63|
| TAC (Total Antioxidant Capacity, µmol H2O2/L) | 326.5 ± 85.0  | 332.2 ± 81.5      | .83|
| PON-1 (Paraoxonase-1 levels, U/L) | 2723.3 ± 315.9 | 2808.1 ± 367.7    | .44|

**Role of oxidative stress and PON-1 in PMDD**

Previous studies have reported decreased antioxidant levels and increased oxidative and nitrosative stress...
pathway activities in subjects with depression [44-46]. Further, antidepressants have been shown to reduce oxidative and nitrosative stress pathway activations in both clinical depression and animal models, strongly indicating that inflammatory processes are involved in depression [46].

**Table 2.** TAC, TOS, PON-1, estrogen, and progesterone levels in patients with PMDD and controls.

|                      | Follicular phase | Luteal phase |
|----------------------|-----------------|--------------|
|                      | PMDD            | Control      | PMDD          | Control      | p          |
| **TAC (Total antioxidant capacity)** (mmol/Trolox Eq/L) |                 |              |               |              |           |
| First cycle          | 346.1 ± 127.4   | 341.7 ± 139.9| 306.8 ± 117.0 | 327.8 ± 137.2| .589       |
| Second cycle         | 336.6 ± 115.5   | 314.4 ± 98.3 | 357.9 ± 115.3 | 325.7 ± 101.8| .401       |
| Mean of both cycles  | 332.0 ± 93.8    | 330.8 ± 99.6 | 322.7 ± 111.1 | 319.0 ± 89.45| .9         |
| ΔTotal antioxidant   | −28             | 46           | 28            | −46          | .349*      |
| (median, percentiles 25–75%) | (−163,62.3)    | (−140,242.5) | (−68.3,163)   | (−242.5,140) |           |
| **TOS (Total oxidant status)** (µmol H₂O₂/L) |                 |              |               |              |           |
| First cycle          | 39.8 ± 21.9     | 33.6 ± 14.3  | 35.8 ± 9.20   | 34.2 ± 16.8  | .712       |
| Second cycle         | 27.9 ± 7.3      | 35.4 ± 11.8  | 36.3 ± 15.8   | 43.2 ± 14.9  | .201       |
| Mean of both cycles  | 36.1 ± 19.9     | 33.8 ± 8.4   | 35.8 ± 8.9    | 37.7 ± 14.9  | .61        |
| ΔTotal oxidant*      | −4              | 2.5          | 2             | 6            | .139*      |
| (median, percentiles 25–75%) | (−22.3,13.3)   | (−11.5,13.3) | (−12.5,14.8)  | (−1.5,30.5)  |           |
| **PON-1 levels** (U/L) |                 |              |               |              |           |
| First cycle          | 2717.3 ± 461.0  | 2924.5 ± 496.6| .169          | 2777.2 ± 487.1| 2728.3 ± 410.2| .711       |
| Second cycle         | 2775.7 ± 514.7  | 2744.2 ± 445.2| .844          | 2466.7 ± 437.3| 2813.2 ± 575.1| .062       |
| Mean of both cycles  | 2795.0 ± 418.4  | 2830.3 ± 399.3| .779          | 2643.2 ± 390.0| 2771.3 ± 434.4| .31        |
| ΔPON-1*              | −102            | −153         | −155.5        | 21           | .037*      |
| (median, percentiles 25–75%) | (−247.5,335)   | (−764.8,331.5)| (−805.5,22.8) | (−170,600)  |           |
| **Estrogen levels** (pg/mL) |                 |              |               |              |           |
| First cycle          | 52.7 ± 38.7     | 52.9 ± 35.1  | 116.6 ± 53.7  | 159 ± 114.2  | .134       |
| Second cycle         | 49.5 ± 22.4     | 83.6 ± 77.0  | 116.8 ± 46.7  | 116.8 ± 84.3 | .99        |
| Mean of both cycles  | 50.7 ± 25.4     | 69.1 ± 46.7  | 116.0 ± 38.10 | 129.1 ± 90.9 | .56        |
| ΔEstrogen*           | 0.6             | 0.3          | −5            | 46.9         | .108*      |
| (median, percentiles 25–75%) | (−30.1,14.9)  | (−97,225.5)  | (−33.9,20.4)  | (−81,11.2)  |           |
| **Progesterone levels** (ng/mL) |                 |              |               |              |           |
| First cycle          | 1.9 ± 3.5       | 1.7 ± 3.8    | 9.6 ± 9.9     | 12.5 ± 18.7  | .507       |
| Second cycle         | 1.3 ± 2.5       | 2.0 ± 3.0    | 6.4 ± 5.90    | 5.7 ± 5.7    | .715       |
| Mean of both cycles  | 1.7 ± 2.8       | 2.1 ± 3.8    | 8.4 ± 6.90    | 8.9 ± 9.2    | .83        |
| ΔProgesterone*       | 0               | 0.1          | −1.3          | −1.2         | .795*      |
| (median, percentiles 25–75%) | (−0.1,0.1)     | (−0.1,0.1)  | (−7.7,2.8)    | (−8.8,1.7)  |           |

*Mann–Whitney U test, others t-test. For Δ values median (percentiles 25–75%), for others mean ± SD.

**Figure 2.** TAC in patients with PMDD and controls for two consecutive menstrual phases. TAC: Total antioxidant capacity, PMDD: premenstrual dysphoric disorder.  

**Figure 3.** TOS in patients with PMDD and controls for two consecutive menstrual phases. TOS: total oxidant status, PMDD: premenstrual dysphoric disorder.
Recently, the hypothesis about that PMDD may involve increased inflammatory processes [29] has been expanded to include a role of progesterone withdrawal in the release of inflammatory products such as nuclear factor-κB and tumor necrosis factor [47]. However, to date conflicting results have been obtained with regard to the involvement of oxidative stress and PMS. In a preliminary study, subjects with PMS showed no evidence of oxidative damage [48]. In two studies that used malondialdehyde (MDA) as a marker of oxidative stress, no difference was observed between PMS patients and controls [5,49]. Conversely, a study by Duvan et al. [5] reported a significant difference in LPH levels between controls and patients with PMS, and they found that TAC was significantly decreased in the PMS group. Importantly, the authors did not evaluate well-known confounding factors such as depression, anxiety, and sleep quality. In this study, we did not find any statistically significant differences in mean serum total oxidant, antioxidant, or PON-1 levels between the PMDD and control groups of two menstrual cycles.

We did measure a statistically significant difference in ΔPON-1 between the PMDD and control groups. This protein is produced primarily in the liver but is also expressed in cells throughout the body, including endothelial cells and macrophages [50,51]. A polymorphism on PON-1 (Q192R) was previously associated with depression [52] and bipolar disorder [34]. A previous study described lower levels of PON-1 in patients with depression compared with controls and found altered PON-1 levels in patients following treatment with citalopram [53]. This suggests that PON-1 may play a role in PMDD pathophysiology. We noted that PON-1 was higher during the follicular phase in subjects with PMDD and in the luteal phase in controls (Figure 3). Indeed, we found opposite patterns for serum total oxidant, antioxidant, and PON-1 levels in PMDD and controls. Although these findings were not statistically significant, they might reflect different onsets of inflammatory reactions that cause women to be symptomatic or asymptomatic during their late luteal phases.

**Role of estrogen and progesterone in PMDD pathophysiology**

As expected, progesterone and estrogen levels were found higher during the luteal phase, but we found no statistically significant difference between PMDD patients and controls. We found that Aestrogen levels in both luteal phases were found as positively, mildly, and statistically significantly correlated with PAF scores that suggests the severity of the PMS. Etiological studies have described increases in these hormones during the premenstrual cycle [13,54], but another group reported no differences in estrogen and progesterone levels in subjects with PMS [15]. In a study that examined to reduce progesterone sensitivity by altering receptor levels [55] and in another study [56], an increased proportion of subjects with PMS were found to have an estrogen1 receptor polymorphism. We speculated that increases in estrogen and progesterone levels in PMDD might have been a compensatory mechanism to ameliorate oxidant mechanisms. The protective functions of these female hormones could underlie these unexpected results since estrogen and progesterone have been shown to prevent oxidative stress [57]. Another group demonstrated how estrogen might enhance an antioxidant mechanism via anti-inflammatory effects [58]. Collectively, the evidence in the literature suggests that estrogen and progesterone may have indirect roles in PMDD pathophysiology via their receptors rather than a direct effect due to their serum levels.

**Correlation of sleep, depression, and anxiety with PON-1 and oxidative stress levels**

Sleep, depression, and anxiety scores were evaluated in subjects with PMDD, as were the relationships of these variables with total oxidant–antioxidant and PON-1 levels. A limited number of clinical studies have evaluated how sleep effectiveness impacts oxidative stress [59,60]. It has been proposed that cerebral free radicals accumulate during wakefulness and are removed during sleep [61]. Poor sleep quality was previously associated with higher levels of the oxidative stress factor MDA and lower levels of the antioxidants
glutathione and glutathione peroxidase [62]. Conversely, MDA, xanthine oxidase (XO), superoxide dismutase (SOD), glutathione peroxidase (GPx), and catalase, which are often presumed to be principal mediators of oxidative stress, remained unchanged in healthy individuals who were sleep deprived for 24 h [63]. Interestingly, women with severe PMDD reported subjectively but significantly poorer sleep quality during the late luteal phase; however, polysomnograms indicated no evidence of disturbed sleep specific to symptoms [64]. We used the PSQI and did not find a difference in sleep quality between PMDD patients and controls in either menstrual phase.

A lifetime comorbidity history of anxiety or other mood disorders has been reported in more than 50% of women presenting with PMS [65]. Anxiety and oxidant and antioxidant levels were explored in patients with sleep bruxism; however, the effect of anxiety itself on oxidant and antioxidant levels has not been explored [66]. Impaired immune function and increased cytokine release, probably due to augmented cortisol secretion that could lead to oxidative stress as indicated by lowered plasma TAC has been reported in women with anxiety [67]. Whether an imbalanced oxidant–antioxidant status underlies gamma-amino-n-butyric acidergic activity in PMS patients or is secondary to excessive opioid activity in PMS remains unknown [67]. In our research, HARS and HDRS scores were higher in PMDD patients than controls, but this was not due to increased oxidative stress in the blood, and further investigations on other possible mechanisms underlying vulnerability to depression and anxiety in PMDD patients are warranted. Interestingly, the mean luteal HARS score was negatively near to statistically significantly correlated with the mean luteal PON-1 level in the same cycle. We think that these data deserve further analysis as PON-1 levels may be important in the pathophysiology of anxiety or vice versa. Similarly, PAF scores were positively correlated with second-cycle follicular phase oxidant levels, suggesting that some PMDD symptoms may also manifest in the follicular phase.

To our knowledge, this is the first study evaluating estrogen, progesterone, total oxidant–antioxidant, and PON-1 levels in patients with PMDD and examining possible correlations with depression, anxiety, and sleep quality.

**Limitations**

We only assessed a small number of subjects including young females, which may explain the lack of significant findings. Despite this shortcoming, we controlled for possible confounding factors that would impact oxidant and antioxidant levels, such as age, BMI, dietary habits. Moreover, subjects were excluded if they reported any of the following: smoking, long-term medication usage, hypertension, hyperlipidemia, or diabetes.

**Conclusion**

In conclusion, the serum levels of estrogen, progesterone, oxidant–antioxidants, and PON-1 were not found to be altered in the PMDD patients. Hence, these findings of the present study did not prove our initial hypothesis that oxidative stress and neuroendocrine factors might influence PMDD symptoms. Therefore, evidence to support the hypothesis proposed by earlier studies that suggest associations between PMDD and oxidative stress and related cellular mechanisms remains elusive. Additional longitudinal studies with larger sample sizes that will examine possible role of inflammatory processes in the pathophysiology of PMDD are needed to clarify PMDD pathogenesis.

**Disclosure statement**

No potential conflict of interest was reported by the authors.

**References**

[1] Barnhart KT, Freeman EW, Sondheimer SJ. A clinician’s guide to the premenstrual syndrome. Med Clin North Am. 1995;79(6):1457–1472.
[2] Pearlstein T, Steiner M. Premenstrual dysphoric disorder: burden of illness and treatment update. J Psychiatry Neurosci. 2008;33(4):291–301.
[3] Rapkin AJ, Winer SA. Premenstrual syndrome and premenstrual dysphoric disorder: quality of life and burden of illness. Expert Rev Pharmacoecon Outcomes Res. 2009;9(2):157–170.
[4] APA (American Psychiatric Association). Diagnostic and statistical manual of mental disorders. 5th ed. Washington (DC): American Psychiatric Press; 2013.
[5] Duvan CJ, Cumaoglu A, Turhan NO, et al. Oxidant/antioxidant status in premenstrual syndrome. Arch Gynecol Obstet. 2011;283(2):299–304.
[6] Zachar P, Kendler KS. A diagnostic and statistical manual of mental disorders history of premenstrual dysphoric disorder. J Nerv Ment Dis. 2014;202(4):346–352.
[7] Braverman PK. Premenstrual syndrome and premenstrual dysphoric disorder. J Pediat Adolesc Gynecol. 2007;20(1):3–12.
[8] Batra NA, Seres-Mailo J, Hanstock C, et al. Proton magnetic resonance spectroscopy measurement of brain glutamate levels in premenstrual dysphoric disorder. Biol Psychiatry. 2008;63(12):1178–1184.
[9] Cubeddu A,ucci F, Giannini A, et al. Brain-derived neurotrophic factor plasma variation during the different phases of the menstrual cycle in women with premenstrual syndrome. Psychoneuroendocrinology. 2011;36(4):523–530.
[10] Inoue Y, Terao T, Iwata N, et al. Fluctuating serotoninergic function in premenstrual dysphoric disorder and premenstrual syndrome: findings from neuroendocrine challenge tests. Psychopharmacology (Berl). 2006;190(2):213–219.
[11] Rapkin AJ, Mikacich JA. Premenstrual syndrome and premenstrual dysphoric disorder in adolescents. Curr Opin Obstet Gynecol. 2008;20(5):455–463.

[12] Dereboy C, Dereboy IF, Yigitol F. Psychometric data for the premenstrual assessment form: a cluster analytic study. Turk Psikiyatri Derg. 1994;5(2):583–590.

[13] Mingqi Q, Huiyun Z, Yanhong Y, et al. Dynamic changes in serum estradiol and progesterone levels in patients of premenstrual syndrome with adverse flow of liver-qi. J Tradit Chin Med. 2008;28(2):106–109.

[14] Steiner M. Premenstrual syndrome and premenstrual dysphoric disorder: guidelines for management. J Psychiatry Neurosci. 2000;25(5):459–468.

[15] Rapkin AJ, Akopians AL. Pathophysiology of premenstrual syndrome and premenstrual dysphoric disorder. Menopause Int. 2012;18(2):52–59.

[16] Mortola JF. Premenstrual syndrome – pathophysiological considerations. N Engl J Med. 1998;338(4):256–257.

[17] Steiner M, Pearlstein T. Premenstrual dysphoria and the serotonin system: pathophysiology and treatment. J Clin Psychiatry. 2000;61(Suppl.12):S17–S21.

[18] Atmaca M, Kuloğlu M, Tezcan E, et al. Antioxidant enzyme and malondialdehyde levels in patients with social phobia. Psychiatry Res. 2008;159(1–2):95–100.

[19] Herken H, Uz E, Ozyurt H, et al. Evidence that the activities of erythrocyte free radical scavenging enzymes and the products of lipid peroxidation are increased in different forms of schizophrenia. Mol Psychiatry. 2001;6(1):66–73.

[20] Ramanathan L, Gulyani S, Nienhuis R, et al. Sleep deprivation decreases superoxide dismutase activity in rat hippocampus and brainstem. Neuroreport. 2002;13(11):1387–1390.

[21] Savas HA, Herken H, Yurekli M, et al. Possible role of nitric oxide and adrenomedullin in bipolar affective disorder. Neuropsychobiology. 2002;45(2):57–61.

[22] Suer C, Dola N, Artis AS, et al. The effects of long-term sleep deprivation on the long-term potentiation in the dentate gyrus and brain oxidation status in rats. Neurosci Res. 2011;70(1):77–77.

[23] Tsalučhidu S, Cocchi M, Tonello L, et al. Fatty acids and oxidative stress in psychiatric disorders. BMC Psychiatry. 2008;8(Suppl.1):S5.

[24] Maes M, Bosmans E, Suy E, et al. Immune disturbances during major depression: upregulated expression of interleukin-2 receptors. Neuropsychobiology. 1990–1991;24(3):115–120.

[25] Maes M, Bosmans E, Suy E, et al. Depression-related disturbances in mitogen-induced lymphocyte responses and interleukin-1 beta and soluble interleukin-2 receptor production. Acta Psychiatr Scand. 1991;84(4):379–386.

[26] Maes M, Lambrechts J, Bosmans E, et al. Evidence for a systemic immune activation during depression: results of leukocyte enumeration by flow cytometry in conjunction with monoclonal antibody staining. Psychol Med. 1992;22(1):45–53.

[27] Maes M, Scharpe S, Meltzer HY, et al. Increased neopterin and interferon-gamma secretion and lower availability of L-tryptophan in major depression: further evidence for an immune response. Psychiatry Res. 1994;54(2):143–160.

[28] Maes M, Wauters A, Verkerk R, et al. Lower serum L-tryptophan availability in depression as a marker of a more generalized disorder in protein metabolism. Neuropsychopharmacology. 1996;15(3):243–251.

[29] Finn CA. Implantation, menstruation and inflammation. Biol Rev Camb Philos Soc. 1986;61(4):313–328.

[30] Puder JJ, Blum CA, Mueller B, et al. Menstrual cycle symptoms are associated with changes in low-grade inflammation. Eur J Clin Invest. 2006;36(1):58–64.

[31] Bertone-Johnson ER, Ronnenberg AG, Houghton SC, et al. Association of inflammation markers with menstrual symptom severity and premenstrual syndrome in young women. Hum Reprod. 2014;29(9):1987–1994.

[32] Incebiyik A, Camuuzzuoglu A, Hilali NG, et al. Serum oxidative stress, visfatin and apelin in healthy women and those with premenstrual syndrome. J Obstet Gynaecol. 2015;35(2):188–192.

[33] Keaney Jr JF, Larson MG, Vasan RS, et al. Obesity and systemic oxidative stress: clinical correlates of oxidative stress in the Framingham Study. Arterioscler Thromb Vasc Biol. 2003;23(3):434–439.

[34] Bortolasci CC, Vargas HO, Souza-Nogueira A, et al. Lowered plasma paraoxonase (PON)1 activity is a trait marker of major depression and PON-1 Q192R gene polymorphism-smoking interactions differentially predict the odds of major depression and bipolar disorder. J Affect Disord. 2014;159:23–30.

[35] Endicott J, Nee J, Harrison W. Daily record of severity of problems (DRSP): reliability and validity. Arch Womens Ment Health. 2006;9(1):41–49.

[36] Halbreich U, Endicott J, Schacht S, et al. The diversity of premenstrual changes as reflected in the Prenenstrual Assessment Form. Acta Psychiatr Scand. 1982;65(1):46–65.

[37] Buyssse DJ, Reynolds CF, Monk TH, et al. The Pittsburgh Sleep Quality Index: a new instrument for psychiatric practice and research. Psychiatry Res. 1989;28(2):193–213.

[38] Argun M, Kara H, Anlar O. The validity and reliability of the Pittsburgh Sleep Quality Index. Turkish J Psychiatry. 1996;7(2):107–115. Turkish.

[39] Williams JB. A structured interview guide for the Hamilton Depression Rating Scale. Arch Gen Psychiatry. 1988;45(8):742–747.

[40] Akdemir A, Orsel S, Dag I, et al. The validity and reliability of the Hamilton Depression Rating Scale. Psikiyatri Psikofarmakoloji Dergisi. 1996;4(4):251–259.

[41] Hamilton M. The assessment of anxiety states by raters and self-raters. A preliminary report. Br J Med Psychol. 1959;32(1):50–55.

[42] Yazıcı MK, Demir B, Tanriverdi N, et al. Hamilton Anxiety Rating Scale: interrater reliability and validity study. Turkish J Psychiatry. 1998;9(2):114–117.

[43] Aslan M, Nazligul Y, Horoz M, et al. Serum paraoxonase-1 activity in Helicobacter pylori infected subjects. Atherosclerosis. 2008;196(1):270–274.

[44] Bilici M, Efe H, Koroglu MA, et al. Antioxidative enzyme activities and lipid peroxidation in major depression: alterations by antidepressant treatments. J Affect Disord. 2001;64(1):43–51.

[45] Maes M, De Vos N, Pioli R, et al. Lower serum vitamin E concentrations in major depression. Another marker of lowered antioxidant defenses in that illness. J Affect Disord. 2000;58(3):241–246.

[46] Maes M, Galecki P, Chang YS, et al. A review on the oxidative and nitrosative stress (O&NS) pathways in major depression and their possible contribution to the (neuro)degenerative processes in that illness. Prog Neuropsychopharmacol Biol Psychiatry. 2011;35(3):676–692.
[47] Evans J, Salamonsen LA. Inflammation, leukocytes and menstruation. Rev Endocr Metab Disord. 2012;13(4):277–288.
[48] Kalia G, Sudhindran S, Rao A. Antioxidant status and lipid peroxidation in premenstrual syndrome: a preliminary study. Clin Chim Acta. 2001;309(1):97–99.
[49] Balat O, Dikensoy E, Ugur MG, et al. Malondialdehyde, nitrite and adrenomedullin levels in patients with premenstrual syndrome. Arch Gynecol Obstet. 2007;275(5):361–365.
[50] Ng CJ, Shih DM, Hama SY, et al. The paraoxonase gene family and atherosclerosis. Free Radic Biol Med. 2005;38(2):153–163.
[51] Thiersch M, Raffelsberger W, Frigg R, et al. Analysis of the retinal gene expression profile after hypoxic preconditioning identifies candidate genes for neuroprotection. BMC Genomics. 2008;9:73.
[52] Lawlor DA, Day IN, Gaunt TR, et al. The association of the paraoxonase (PON-1) Q192R polymorphism with depression in older women: findings from the British Women’s Heart and Health Study. J Epidemiol Community Health. 2007;61(1):85–87.
[53] Barim AO, Aydin S, Colak R, et al. Ghrelin, paraoxonase and arylesterase levels in depressive patients before and after citalopram treatment. Clin Biochem. 2009;42(10–11):1076–1081.
[54] Nathan I, Chaudhuri G. Antioxidant and prooxidant actions of estrogens: potential physiological and clinical implications. Semin Reprod Endocrinol. 1998;16(4):309–314.
[55] Baker LJ, O’Brien PM. Premenstrual syndrome (PMS): a peri-menopausal perspective. Maturitas. 2012;72(2):121–125.
[56] Poiana C, Musat M, Carsote M, et al. Premenstrual dysphoric disorder: neuroendocrine interferences. Rev Med Chir Soc Med Nat Iasi. 2009;113(4):996–1000.
[57] Yagi K. Female hormones act as natural antioxidants – a survey of our research. Acta Biochim Pol. 1997;44(4):701–709.
[58] Haji Hussein I, Eid A, Masoud R, et al. Estrogens control inflammation in experimental colitis. J Biol Regul Homeost Agents. 2014;28(2):213–224.
[59] Lavi L. Obstructive sleep apnoea syndrome – an oxidative stress disorder. Sleep Med Rev. 2003;7(1):35–51.
[60] Schulz R, Mahmoudi S, Hattar K, et al. Enhanced release of superoxide from polymorphonuclear neutrophils in obstructive sleep apnea. Am J Respir Crit Care Med. 2000;162(2 Pt 1):566–570.
[61] Reimund E. The free radical flux theory of sleep. Med Hypotheses. 1994;43(4):231–233.
[62] Gulec M, Ozkol H, Selvi Y, et al. Oxidative stress in patients with primary insomnia. Prog Neuropsychopharmacol Biol Psychiatry. 2012;37(2):247–251.
[63] Aytac B, Kayhan A, Devrim E, et al. The effects of sleep deprivation on oxidant/antioxidant status. Klinik Psikofarmakoloji Bulteni-Bulletin of Clinical Psychopharmacology. 2007;17(3):130–133. Turkish.
[64] Baker FC, Kahan TL, Trinder J, et al. Sleep quality and the sleep electroencephalogram in women with severe premenstrual syndrome. Sleep. 2007;30(10):1283–1291.
[65] Huffman JW, Dai D, Martin BR, et al. Design, synthesis and pharmacology of cannabimimetic indoles. Bioorg Med Chem Lett. 1994;4(4):563–566.
[66] Kara MI, Yanik S, Keskinruzgar A, et al. Oxidative imbalance and anxiety in patients with sleep bruxism. Oral Surg Oral Med Oral Pathol Oral Radiol. 2012;114(5):604–609.
[67] Arranz L, Guayerbas N, De la Fuente M. Impairment of several immune functions in anxious women. J Psychosom Res. 2007;62(1):1–8.